BeyondSpring Inc Stock News

Bank of America lowered shares of BeyondSpring (NASDAQ:BYSI) from a buy rating to an underperform rating in a research report released on Wednesday, Price Targets.com reports. The firm currently has $5.00 price objective on the stock, down from their prior price objective of $45.00. Several other research firms also recently commented on BYSI. Evercore ISI []

BeyondSpring (NASDAQ:BYSI) had its price objective decreased by investment analysts at Evercore ISI from $95.00 to $25.00 in a research note issued on Thursday, The Fly reports. The brokerage presently has an outperform rating on the stock. Other equities research analysts have also recently issued reports about the stock. Bank of America cut shares of []

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy For A Short Squeeze? 5 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy For A Short Squeeze?

BeyondSpring (NASDAQ:BYSI) was downgraded by equities researchers at Bank of America from a buy rating to an underperform rating in a research note issued on Wednesday, Price Targets.com reports. They currently have a $5.00 target price on the stock, down from their previous target price of $45.00. Bank of Americas target price suggests a potential [] The post Bank of America Downgrades BeyondSpring (NASDAQ:BYSI) to Underperform appeared first on ETF Daily News .

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BeyondSpring, Inc. (NASDAQ: BYSI) for potential securities law violations. Investors who have lost money in their BeyondSpring investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/bysi .

Charles Schwab Investment Management Inc. raised its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 17.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,461 shares of the companys stock after acquiring an additional 6,915 shares during the quarter. Charles Schwab Investment Management Inc. []

HC Wainwright downgraded shares of BeyondSpring (NASDAQ:BYSI) from a buy rating to a neutral rating in a report published on Wednesday, Analyst Price Targets reports. Several other research firms also recently weighed in on BYSI. Evercore ISI reissued a buy rating on shares of BeyondSpring in a report on Thursday, August 19th. William Blair reissued []

The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Inc''s (NASDAQ: BYSI ) marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN). The application covers plinabulin in combination with granulocyte colony-stimulating factor (G-CSF). Related:

BeyondSpring Inc (NASDAQ: BYSI) is trading significantly lower Wednesday after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for

The stock price of BeyondSpring Inc (NASDAQ: BYSI) fell by over 55% during intraday trading today. This is why it happened.

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the Company or BeyondSpring) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its present form.

The FDA has issued a Complete Response Letter to BeyondSpring Pharmaceuticals Inc's (NASDAQ: BYSI) marketing application seeking approval for plinabulin to prevent chemotherapy-induced neutropenia